急性心肌梗塞(AMI)病人出院後三個月以內給藥比率-乙型阻斷劑(β-Blocker)(疾病別指標)

健保署為加強心肌梗塞病患醫療品質，擇定具實證醫學指標項目作公開，作為相關疾病就醫時或健康照護品質的參考；公開項目依治療期間及品質面向共分三大類，包括住院期間過程面評估、出院持續藥物治療評估及結果面評估。包含急性心肌梗塞(AMI)病人於住院期間執行血脂LDL檢查比率、急性心肌梗塞(AMI)病人於住院期間、出院後三個月、六個月、九個月內給藥比率、病人出院後三日以內因同一主診斷或相關病情之急診返診比率、病人出院後十四日以內因同一主診斷或相關病情之非計畫性再住院比率等。

The National Health Insurance Administration has selected evidence-based medical indicators to enhance the quality of medical care for patients with myocardial infarction. These indicators are made public as references for medical treatment of related diseases or the quality of healthcare. The public items are divided into three major categories based on the treatment period and quality aspects, including process assessment during hospitalization, continuous medication treatment assessment after discharge, and outcome assessment. The dataset includes the ratio of lipid LDL tests performed on patients with acute myocardial infarction (AMI) during hospitalization, medication administration ratios for patients with AMI during hospitalization and within three months, six months, and nine months after discharge, emergency return visit ratios within three days after discharge due to the same main diagnosis or related conditions, and unplanned rehospitalization ratios within fourteen days after discharge due to the same main diagnosis or related conditions.